Advanced Ovarian Cancer Clinical Trial
Official title:
Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer
Our study aims at assessment of response, survival and toxicity of frontline treatment with chemotherapy and Bevacizumab in patients having advanced epithelial ovarian cancer.
Status | Not yet recruiting |
Enrollment | 40 |
Est. completion date | September 1, 2022 |
Est. primary completion date | August 31, 2022 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Female patients diagnosed with advanced ovarian cancer by biopsy - Age more than 18 years old - Routine labs are within normal values ( CBC, renal function tests , liver function tests ) - Performance score 0-2 - FIGO stage II-IV - Not having any contraindication to bevacizumab as : uncontrolled hypertension , bleeding tendency , ischaemic events - Chemotherapy naïve. - Informed consent Exclusion Criteria: - patients previously received chemotherapy or radiotherapy to any part of the abdomen or pelvis - patients with uncontrolled infection - patients with clinically significant cardiovascular disease - patients with active bleeding or conditions associated with high risk of bleeding - patients with history of CNS disease |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Nada Hassan Salah | Assiut University |
Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, Peltomäki P, Mecklin JP, Järvinen HJ. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 1999 Apr 12;81(2):214-8. — View Citation
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7. — View Citation
Wright AA, Cronin A, Milne DE, Bookman MA, Burger RA, Cohn DE, Cristea MC, Griggs JJ, Keating NL, Levenback CF, Mantia-Smaldone G, Matulonis UA, Meyer LA, Niland JC, Weeks JC, O'Malley DM. Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer. J Clin Oncol. 2015 Sep 10;33(26):2841-7. doi: 10.1200/JCO.2015.61.4776. Epub 2015 Aug 3. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | progression free survival | determination of time from starting treatment until first progression | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06055348 -
SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT04135521 -
Dose-dense Chemotherapy Versus Intraperitoneal Chemotherapy as First-line Chemotherapy in Advanced Ovarian Cancer
|
||
Completed |
NCT01462149 -
Efficacy Study of Neoadjuvant Chemotherapy to Treat Advanced Ovarian Cancer
|
Phase 2 | |
Terminated |
NCT03292172 -
A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
|
Phase 1 | |
Not yet recruiting |
NCT05794659 -
Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer
|
Phase 2 | |
Completed |
NCT04360629 -
Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer
|
N/A | |
Completed |
NCT00516724 -
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel
|
Phase 1 | |
Completed |
NCT03158935 -
The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial
|
Phase 1 | |
Completed |
NCT05775549 -
A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer
|
||
Active, not recruiting |
NCT03737643 -
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
|
Phase 3 | |
Completed |
NCT01290471 -
Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors
|
Phase 1 | |
Recruiting |
NCT04862325 -
SOPHIE Trial: Surgery in Ovarian Cancer With PreHabilitation In ERAS
|
N/A | |
Completed |
NCT01989546 -
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
|
Phase 1/Phase 2 | |
Recruiting |
NCT04556539 -
Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer
|
Phase 2 | |
Completed |
NCT03161132 -
Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin
|
Phase 2 | |
Active, not recruiting |
NCT04065009 -
The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer
|
Phase 3 | |
Active, not recruiting |
NCT01844986 -
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
|
Phase 3 | |
Not yet recruiting |
NCT05924776 -
Plasmodium Immunotherapy for Advanced Ovarian Cancer
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03878849 -
Investigation of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP®
|
Phase 2 |